A c-Met directed antibody-drug conjugate shows preliminary activity in a NSCLC cohort
Efficacy and safety of telisotuzumab adizutecan was investigated in patients with EGFR wild type non-squamous disease
Efficacy and safety of telisotuzumab adizutecan was investigated in patients with EGFR wild type non-squamous disease
The combination therapy with the CDK 4/6 inhibitor improved overall response rate compared to standard treatment
Strategies to target MTAP deletion, KRAS G12D and ESR1 mutations, and CDK4 and CDK2 further expand the landscape of precision oncology
Data from studies presented highlight the importance of integrating and incorporating comprehensive genomic profiling into clinical practice across a broad range of tumour types
However, the future of TKI combinations for these rare tumours is uncertain
New data from the ALINA study confirm lack of influence of EML4-ALK variant on outcome in this patient population
Study findings indicate that the agent is promising as maintenance therapy, but managing its tolerability presents challenges
Early-phase clinical trial results show promise to optimise the current standard of care by using dual-targeting agents and investigating the most effective chemotherapy backbone for PD-L1 blockade
Overall survival benefits of systemic therapy in the adjuvant setting are still unclear in clinical trials, and may need to be complemented with real-world studies
Preliminary results from three clinical trials reveal some benefits of cetuximab plus irinotecan, amivantamab plus FOLFOX or FOLFIRI and ramucirumab plus standard of care for patients with mCRC, including after progression on standard therapies
This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.
For more detailed information on the cookies we use, please check our Privacy Policy.
Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.